Evidence map›Paper›PMID 36338887›Full record

ReviewWorld journal of gastroenterology2022

Receptor of advanced glycation end-products axis and gallbladder cancer: A forgotten connection that we should reconsider.

Armando Rojas, Cristian Lindner, Iván Schneider, Ileana Gonzàlez, Miguel Angel Morales

Open access · greenAbstract readReview
In one paragraph

Review in World journal of gastroenterology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Association between dietary advanced glycation end products and gallstone disease: A case-control study.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2026
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Armando RojasBiomedical Research Laboratories, Catholic University of Maule, Talca 34600000, Maule, Chile. arojasr@ucm.cl.
Cristian LindnerMedicine Faculty, Catholic University of Maule, Talca 34600000, Maule, Chile.
Iván SchneiderMedicine Faculty, Catholic University of Maule, Talca 34600000, Maule, Chile.
Ileana GonzàlezBiomedical Research Laboratories, Catholic University of Maule, Talca 34600000, Maule, Chile.
Miguel Angel MoralesDepartment of Molecular and Clinical Pharmacology Program, Institute of Biomedical Sciences, University of Chile, Santiago 8320000, Santiago, Chile.
Catholic University of the Maule · CLUniversidad de Santiago de Chile · CL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Compelling evidence derived from clinical and experimental research has demonstrated the crucial contribution of chronic inflammation in the development of neoplasms, including gallbladder cancer. In this regard, data derived from clinical and experimental studies have demonstrated that the receptor of advanced glycation end-products (RAGE)/AGEs axis plays an important role in the onset of a crucial and long-lasting inflammatory milieu, thus supporting tumor growth and development. AGEs are formed in biological systems or foods, and food-derived AGEs, also known as dietary AGEs are known to contribute to the systemic pool of AGEs. Once they bind to RAGE, the activation of multiple and crucial signaling pathways are triggered, thus favoring the secretion of several proinflammatory cytokines also involved in the promotion of gallbladder cancer invasion and migration. In the present review, we aimed to highlight the relevance of the association between high dietary AGEs intakes and high risk for gallbladder cancer, and emerging data supporting that dietary intervention to reduce gallbladder cancer risk is a very attractive approach that deserves much more research efforts.

Indexed as

Gallbladder NeoplasmsGlycation End Products, AdvancedCytokinesHumansInflammationReceptor for Advanced Glycation End ProductsCytokinesGlycation End Products, AdvancedReceptor for Advanced Glycation End ProductsAdvanced glycation end-productsChronic inflammationGallbladder cancerNutritionReceptor of advanced glycation end-products

Identifiers

PMID36338887
PMCPMC9627425
OpenAlexW4306654033

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.